From March 9-12, 2013 top women’s cancer doctors from all over the world met in Los Angeles for the Society of Gynecologic Oncology‘s Annual Meeting on Women’s Cancer. Lots of exciting research was presented at the meeting, representing the latest in the care and treatment of women with ovarian and other gynecologic cancers. Highlights from research … Continued
Two studies recently released show a survival benefit for intraperitoneal IP chemotherapy Women with the BRCA1 mutation given IP chemotherapy survived three years longer than those given IV chemotherapy. Read an article about the study here. A study presented at the SGO Annual Meeting showed an improvement in median survival of 10 months.
The New York Times reported today on a study that found most women with ovarian cancer receive inadequate care. The article discusses research presented at the 2013 meeting of the Society of Gynecologic Oncologists (SGO), which found that women are more likely to get optimal care when treated at a medical center that handles a … Continued
Often, patients enrolled in clinical trials live longer than those who are not, however, a new study shows that the survival benefit may be due to the patient’s health, not the treatment received in the clinical trial. Patients interested in clinical trials may also be more involved in decision making, which some believe affects outcomes. … Continued
New research published in Human Reproduction Update provides additional evidence that in vitro fertilization (IVF) does not increase women’s risk for ovarian, endometrial, and cervical cancer. Researchers have wondered if fertility treatments like IVF, which require the use of ovulation-stimulating drugs and the puncturing of the ovaries to retrieve eggs, increased women’s risk of gynecologic cancers. Some … Continued
In a report issued this month, the American Cancer Society released new statistics on cancer in African Americans. Overall, cancer death rates among both African American men and women have declined, yet African Americans still have the highest death rate and shortest survival of any ethnic group for cancer. However, for ovarian cancer, both incidence … Continued
A study of the medical records of more than 67,000 women who underwent fertility treatment found that fertility treatments did not effect the risk of breast or uterine cancer, and may slightly increase the risk of ovarian cancer. Researchers are not sure if the risk of ovarian cancer was due to chance or the drugs/IVF … Continued
A new study published in Endocrine-Related Cancer which used data from the OCRF-funded Ovarian Cancer Association Consortium, evaluated the association between BMI and ovarian cancer risk, and also examined the association by histological subtype, menopausal status, and post-menopausal hormone (HRT) use. Results showed that while obesity does appear to increase risk of less common types of ovarian … Continued
A new report from the American Cancer Society estimates cancer incidence and mortality rates for African Americans. In the case of ovarian cancer, both incidence and mortality are lower for African American women than for white women. Ovarian cancer incidence for African American women is 74 percent of the rate for white women; death rates … Continued
A new study of mice with prostate cancer indicated that stress can hinder the effectiveness of anti-cancer therapies. In this mouse model, the use of beta-blockers did prevent stress from accelerating cancer growth. The pathway will now be tested in human prostate cells. Read an article about the study here and the journal article here. … Continued
In the journal Clinical Cancer Research, a group of researchers, including current and past OCRF grantees Anil Sood and Gabriel Lopez-Berestein, evaluated the prognostic value of fibroblast growth factor receptor 4 (FGFR4) protein expression in patients with advanced-stage, high-grade serous ovarian cancer. They found that FGFR4 is a prognostic marker for the disease. Furthermore, silencing FGFR4 significantly … Continued
A study of 425 Stage III and IV ovarian cancer patients had either primary debulking surgery or interval debulking surgery. Interval debulking surgery did not appear to increase the risk of initial platinum resistance, but did appear to increase the risk of platinum resistance in the recurrent setting. See the abstract here
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
